Proposal of a novel pND-based staging system for locoregional gastric neuroendocrine carcinoma: A multicenter retrospective study.

Y Yukinori Yamagata (Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan) M Mitsuhiro Furuta A Akifumi Notsu (Division of Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan) H Hirofumi Yasui (Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan) R Rie Makuuchi (Department of Gastroenterological Surgery, Cancer Institute Hospital, Koto-Ku, Japan) T Takanobu Yamada (Department of Cardiovascular Medicine (S.N., M.K., T.Y., E.A., K.F., I.K.), University of Tokyo Hospital, University of Tokyo, Japan.) M Michihiro Ishida (Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan) K Kunihiro Tsuji (Departments of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan) S Shigeaki Baba (Department of Surgery, School of Medicine, Iwate Medical University, Morioka, Japan) N Noriaki Tokumoto (Department of Gastroenterological Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan) S Shusuke Haruta (Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan) M Masaya Watanabe T Takuya Hamakawa (Department of Gastroenterological Surgery, Osaka Rosai Hospital, Osaka, Japan) Y Yasuyuki Kawachi (Department of Surgery, Nagaoka Chuo General Hospital, Niigata, Japan) N Norihiko Sugisawa (Department of Surgery, Miyagi Cancer Center, Sendai, Japan) Y Yukinori Kurokawa N Narikazu Boku M Masanori Terashima N Nozomu Machida T Takaki Yoshikawa (National Cancer Center Hospital, Tokyo, Japan)

Abstract

624 Background: Gastric neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy lacking a disease-specific staging system. Our previous multicenter analysis showed therapeutic value of D1 lymphadenectomy, limited benefit of D2, and the prognostic impact of nodal area involvement (pND). The UICC TNM classification (7th edition), based on metastatic node count (pN), had poor prognostic discrimination. We aimed to propose a pND-based staging system and compare its prognostic performance with the UICC TNM classification. Methods: Data of 118 patients with gastric NEC (n=79) or mixed adenoneuroendocrine carcinoma (n=39) who underwent gastrectomy with ≥D1 dissection at 29 Japanese centers (2000–2015) were retrospectively analyzed. Patients with metastasis or preoperative therapy were excluded. Overall survival (OS) and recurrence-free survival (RFS) were estimated by Kaplan–Meier. Prognostic factors were assessed by Cox regression. Model performance was evaluated by likelihood ratio tests, concordance index (C-index), Akaike information criterion (AIC), and Bayesian information criterion (BIC). Results: Median age was 69; 83% male. Five-year OS and 3-year RFS were 56.7% and 63.4%. Older age, female sex, and pND2 were independent adverse prognostic factors. The pND-based system was defined as: Stage A = pT1pND0–1 or pT2–4pND0; Stage B = pT2–4pND1; Stage C = pT2–4pND2. Five-year OS and RFS for A/B/C were 63.5/56.3/40.9% and 58.4/43.7/30.7%. Stage C showed significantly worse OS (HR 2.52, p=0.016) and RFS (HR 2.84, p=0.004) versus Stage A. UICC TNM stages I–III overlapped. Model comparison showed better performance of the pND-based system: OS C-index 0.67 vs 0.62, AIC 498 vs 512, BIC 514 vs 528; RFS C-index 0.65 vs 0.60, AIC 476 vs 489, BIC 492 vs 505. LRT confirmed significant improvement when adding the pND-based stage to UICC TNM, but not vice versa. Conclusions: The pND-based Stage A–C system outperformed the UICC TNM classification (7th edition), offering clearer prognostic stratification. This framework may serve as a disease-specific staging system for gastric NEC and inform surgical and multidisciplinary strategies.

Article Details

Volume / Issue Vol. 44, Issue 2_suppl
Published January 10, 2026
Pages 624-624
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

Y

Yukinori Yamagata

Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan

M

Mitsuhiro Furuta

A

Akifumi Notsu

Division of Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan

H

Hirofumi Yasui

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan

R

Rie Makuuchi

Department of Gastroenterological Surgery, Cancer Institute Hospital, Koto-Ku, Japan

T

Takanobu Yamada

Department of Cardiovascular Medicine (S.N., M.K., T.Y., E.A., K.F., I.K.), University of Tokyo Hospital, University of Tokyo, Japan.

M

Michihiro Ishida

Department of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan

K

Kunihiro Tsuji

Departments of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

S

Shigeaki Baba

Department of Surgery, School of Medicine, Iwate Medical University, Morioka, Japan

N

Noriaki Tokumoto

Department of Gastroenterological Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan

S

Shusuke Haruta

Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan

M

Masaya Watanabe

T

Takuya Hamakawa

Department of Gastroenterological Surgery, Osaka Rosai Hospital, Osaka, Japan

Y

Yasuyuki Kawachi

Department of Surgery, Nagaoka Chuo General Hospital, Niigata, Japan

N

Norihiko Sugisawa

Department of Surgery, Miyagi Cancer Center, Sendai, Japan

Y

Yukinori Kurokawa

N

Narikazu Boku

M

Masanori Terashima

N

Nozomu Machida

T

Takaki Yoshikawa

National Cancer Center Hospital, Tokyo, Japan